Cohance Lifesciences Suryapet Operations Ordered Closed After Fatality

Cohance Lifesciences Limited said the Telangana Pollution Control Board ordered closure of operations at its Suryapet facility on 5 November 2026 after an industrial accident during manufacturing caused one fatality. The event occurred after the 30 September 2026 reporting period, and management said it was undertaking necessary measures in response.

What happened at Cohance Lifesciences’ Suryapet facility?

An industrial accident occurred during the manufacturing process at Cohance Lifesciences’ Suryapet facility after 30 September 2026 and resulted in one fatality. The 6 November 2026 filing does not disclose the accident date, the process involved, the product being made, the cause, or whether there were injuries in addition to the reported fatality.

Cohance Lifesciences disclosed the accident in notes to financial results that its board approved on 6 November 2026. The timing places the event outside both the quarter ended 30 September 2026 and the six months ended 30 September 2026, meaning the reported half-year financial statements do not capture an operating period following the closure direction.

The company identifies its sole reportable segment as Contract Development and Manufacturing Operations, or CDMO. However, the filing does not state Suryapet’s revenue, capacity, output, customer base, inventory, or product mix, so the facility’s contribution to the CDMO segment cannot be quantified from the disclosed information.

What does the Suryapet closure order require?

The Telangana Pollution Control Board, or TGPCB, issued an order dated 5 November 2026 directing the closure of operations at the Suryapet facility. Cohance Lifesciences said management is undertaking necessary measures in response, but did not specify those measures or give a date by which they could be completed.

The filing does not say whether the 5 November 2026 order is temporary or permanent, list conditions for restarting operations, or state whether Cohance Lifesciences has sought a review of the order. It also provides no reopening date, penalty, provision, accident-related insurance claim, or estimate of production and revenue affected by the closure.

The disclosed direction concerns operations at one facility rather than the company’s entire CDMO segment. Still, Cohance Lifesciences has not provided a production-transfer plan, identified alternative plants, or quantified whether orders from Suryapet can be made elsewhere, leaving the practical extent of the disruption unresolved.

What financial position did Cohance Lifesciences report before the closure?

The 5 November 2026 order came after the 30 September 2026 balance-sheet date, so the reported financial position does not measure its subsequent effect. Consolidated total assets were Rs 5,680.18 crore at 30 September 2026, compared with Rs 5,729.64 crore at 31 March 2026, while cash and cash equivalents stood at Rs 98.63 crore.

For the six months ended 30 September 2026, consolidated net cash generated from operating activities was Rs 188.06 crore, down from Rs 261.14 crore in the six months ended 30 September 2025. Inventory increased by Rs 172.03 crore in the latest half-year, compared with an increase of Rs 125.51 crore a year earlier, but the filing does not connect either movement to the later Suryapet accident.

Consolidated purchases of property, plant and equipment were Rs 108.01 crore in the six months ended 30 September 2026, versus Rs 89.71 crore in the corresponding 2025 period. These cash-flow figures offer company-level context only, because Cohance Lifesciences does not disclose capital expenditure or assets by manufacturing site.

What operational impact has Cohance Lifesciences disclosed?

Cohance Lifesciences has not quantified any effect of the Suryapet closure on revenue, costs, customer deliveries, profitability, cash flow or working capital. Its stated response to the 5 November 2026 TGPCB order is limited to management undertaking necessary measures, without production guidance, a customer plan, or an expected closure duration.

The filing provides no comparison between Suryapet’s normal production and output after the closure order. While the company operates in a single CDMO segment, it does not split that segment by facility, customer, geography, product category, or manufacturing stage, preventing a numerical estimate of the site’s share of group operations.

Cohance Lifesciences separately disclosed other post-period developments, including the conversion of compulsorily convertible preference shares in Sapala Organics Private Limited that reduced its shareholding from 67.5% to 51%. Sapala remained a subsidiary, and the filing does not link that ownership change or any other subsequent event to the Suryapet closure.

The same notes say Cohance Lifesciences must acquire an additional 21% shareholding in Sapala based on FY27 performance and the remaining 28% by 31 March 2030. That planned transaction is separate from the 5 November 2026 closure order and does not provide evidence about the timing or terms of a Suryapet reopening.

Conclusion

The disclosed position is that a manufacturing accident at Cohance Lifesciences’ Suryapet facility caused one fatality and led to a TGPCB order dated 5 November 2026 directing the closure of site operations. The filing establishes the regulatory action but does not disclose the accident’s cause, closure conditions, financial cost, affected products, customer exposure, or operational duration.

The next point to watch is management’s response to the TGPCB direction, for which Cohance Lifesciences has disclosed necessary measures but no restoration schedule. A future company update could clarify the conditions for reopening, whether output can move to other CDMO sites, and any quantified impact on revenue, costs, provisions, insurance or customer deliveries.